About Anat Cohen-Dayag
Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Since 2010, Dr. Cohen-Dayag has served as President and CEO of Compugen, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery. Under her leadership, Compugen underwent a strategic transformation to become a therapeutic discovery and development company utilizing its computational discovery expertise to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Dr. Cohen-Dayag holds an MS in Chemical Immunology and a PhD in Cellular Biology, both from the Weizmann Institute of Science.